What was Neuland Laboratories's revenue in Q4 FY26?

Neuland Laboratories reported revenue of ₹776 Cr in Q4 FY26, a +134.9% change year-over-year.

Did Neuland Laboratories management deliver on previous promises?

Scorecard data is being built as historical quarters are processed.

Neuland Laboratories Q4 FY26 Research Workspace: Revenue ₹776 Cr (+134.9%)

Q: What guidance did Neuland Laboratories management give?

Revenue CAGR of 18-20% aspirational over 5 years: Management reiterated the aspirational 18-20% CAGR target over a five-year horizon, though not linearly.

Revenue ₹776 Cr +134.9%

EBITDA ₹319 Cr

PAT ₹213 Cr +667.1%

EBITDA Margin 40%

Duration 60 min

Read Time 1 min read

✓ Verified against BSE filing

2-Minute Summary

✦ AI-Generated from Full Transcript

Neuland Laboratories delivered a record Q4 FY26 with revenue of ₹788.7 crore (up 134.9% YoY), driven by commercial CDMO shipments and favorable exchange rates. EBITDA margin surged to 40.5%, partly due to lumpy revenue timing. PAT jumped to ₹212.5 crore from ₹27.7 crore last year. Full-year revenue grew 37% to ₹2,053 crore, with EBITDA margin expanding to 29.4%. Management reiterated that quarterly lumpiness will persist but long-term growth visibility remains strong, anchored by commercial molecules and peptide investments. The peptide facility is on track for July commissioning. Key risks include demand variability, customer ordering patterns, and geopolitical supply chain disruptions. The company maintains a disciplined capex approach and expects working capital to normalize in FY27.

Risks4 trackedTranscriptfull text

Research workspace

Focused Modules

!Risks 4 risks

Risk Intelligence

Customer M&A could disrupt supply agreements

View Risks →

≡Transcript Full text

Call Transcript

Full transcript text is available on this route.

Read Transcript →

Quarter Snapshot

CDMO Revenue Share ~67%

+42pp YoY

CDMO contributed over two-thirds of Q4 revenue, up from ~25% in Q4 FY25.

Gross Margin 62.1%

+580bps YoY

Gross margin improved to 62.1% from 56.3% last year, driven by favorable business mix.

Capacity Utilization (Unit 1 & 2) 85-90%

flat

Two of three manufacturing units are operating at 85-90% utilization; third unit at 65%.

Working Capital Days 137 days

+30 days YoY

Working capital days increased to 137 from 107 last year due to higher inventories and receivables.

Fast read

Guidance and risk preview

Top guidance Revenue CAGR of 18-20% aspirational over 5 years

Management reiterated the aspirational 18-20% CAGR target over a five-year horizon, though not linearly.

Top risk Customer M&A could disrupt supply agreements

A major customer (Denver/Archimemet) is being acquired; management acknowledged change of ownership could pose risks but expects continuity.